2019

Gastroenterology – Caruso et al – Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.

Item	Data	Details
Cell lines	LCCL_description	Description of liver cancer cell lines.
Cell lines	Somatic_alterations	List of putative somatic genomic alterations identified in 34 Liver Cancer Cell Lines by whole-exome sequencing.
Cell lines	Fusion_transcripts	Fusion transcripts identified in 34 liver cancer cell lines by RNA-sequencing.
Cell lines	HBV_fusions	HBV RNA fusions identified by RNA-sequencing among 34 liver cancer cell lines.
Cell lines	Drivers	List of the 252 cancer driver genes used to analyze association between drug sensitivity and genetic alterations in 34 liver cancer cell lines.
Cell lines	RNAseq_vsn	RNA expression in 34 liver cancer cell lines (vsn)
Cell lines	RNAseq_FPMK	RNA expression in 34 liver cancer cell lines (FPKM)
Cell lines	microRNAseq_vsn	microRNA expression in 34 liver cancer cell lines (vsn)
Cell lines	microRNAseq_RPM	microRNA expression in 34 liver cancer cell lines (RPM)
Cell lines	Protein_expression	Expression of 126 proteins analyzed by RPPA in 34 liver cancer cell lines (log2-transformed).
Cell lines/Drugs	AUC	Drug sensitivity in 34 liver cancer cell lines. Table of AUC values for each drug
Cell lines/Drugs	GI50	Drug sensitivity in 34 liver cancer cell lines. Table of GI50 values for each drug
Drugs	Screened_compounds	Description of screened compounds.

FunGeST Lab – A Multidisciplinary, Young & Motivated Team

Brief history of the team

FunGeST “Functional genomics of solid tumors”, directed by Jessica Zucman-Rossi, was created in 2005, as Inserm U674, it was renewed in 2009 and 2014 as UMR1162, ranked “incontournable” by Inserm as a mixed structure endorsed by four entities: Inserm, Universities Paris Diderot, Paris Descartes and Paris Nord. It is currently located at the University Hematology Institute site in a building managed by the CEPH (Centre d’Etude du Polymorphisme Humain, Foundation Jean Dausset). Since January 2019, the lab take part of Centre de Recherche des Cordeliers Research Center – Inserm UMR S1138 as team 28.

Jessica Zucman-Rossi, is professor of Medicine in Oncology (PUPHex) at university Paris Descartes and HEGP, full time for research. She directed the Inserm U674, U1162 and UMRS1138 – team 28 since 2007, was chairman of the Inserm scientific committee devoted to Oncology, Genetics and Bioinformatics from 2012 to 2016. She is editor at Journal of Hepatology (IF=12.4), executive secretary of the International Liver Cancer Association (ILCA). She published 157 original papers and has an international recognition in the field of genomics of human cancers and more specifically in liver tumors. Since January 2019 Pr Zucman-Rossi-Rossi is the director of the Cordeliers Research Center.

Our missions

Our mission is to develop basic genomic approaches based on human tumors analyses to identify new mechanisms of tumorigenesis and to transfer this knowledge into biomarkers and therapeutic targets that could be introduced in clinical care. In particular, we aim to identify new genomic alterations and mechanisms of carcinogenesis. We also aim to identify new risk factors and genetic predispositions promoting the development of tumors. Our general strategy is based on the omic’s analyses of large cohorts of patients with liver tumors (benign and malignant), mesothelioma and clear cell renal carcinoma. The group was pioneer in the elucidation of the molecular classification of benign and malignant liver tumors. Then we perform (1) functional validation using cell and animal models and (2) we translate our findings into the clinics to improve surveillance, diagnosis, prognosis, treatment and follow-up of the patients.

Our task forces

The team include a total of 39 peoples organized in 5 groups with their founded projects:

“Functional Genomics of Liver tumors” led by Jessica Zucman-Rossi focusing in the characterization of genomic alterations in benign and malignant liver tumors, functional validation, identification of new risk factors and genetic predisposition and translation to the clinics.
“Functional Genomics of Mesothelioma” led by Didier Jean (CR1 Inserm) focusing on the pathogenesis of mesothelioma, search for new therapeutic targets with genomic approaches.
“Therapeutic Targets in liver tumors” led by Sandra Rebouissou (CR2 Inserm) focusing on the identification of therapeutic targets in liver tumors.
“Computational Cancer Genome Analysis” led by Eric Letouzé (CR2 Inserm) focusing on the development and application of innovative strategies for integrative genomic data analysis.
“Genomics of renal cancer” led by Jessica Zucman-Rossi & Benoit Beuselinck (Professor in Louvain)

Tag UMR1138

Our Public Data